Lung Carcinoma — Research

Lung Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	273,384	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	94,693	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	19,676	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (381)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 76–100 of 381 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
· J Thorac Oncol · 2016 · PMID 26899019 · validated civic_curation pubmed
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
· Oncotarget · 2016 · PMID 26918451 · validated civic_curation pubmed
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
· Lancet · 2016 · PMID 26970723 · validated civic_curation pubmed
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.